Healthcare Global Enterprises Ltd

Q4 FY25Healthcare Services

Healthcare Global Enterprises Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management guided on revenue, margins and order book.

Price₹726

Market cap₹10.7K Cr

P/E221.4

Updated23 Aug 2026

Read5 min read

The short version

FY '25 revenue grew 16% to INR 2,223 crores; Q4 revenue rose 18% YoY to INR 585 crores. HCG expects continued strong revenue and EBITDA growth in FY '26, building on a 16-18% revenue growth in FY '25 and a 44% EBITDA increase in emerging centers.

From Healthcare Global Enterprises Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

FY '25 revenue grew 16% to INR 2,223 crores; Q4 revenue rose 18% YoY to INR 585 crores.
Excluding Milann, core HCG centers saw 17% revenue growth and 17% EBITDA growth in FY '25.
Outpatient footfall increased by 13.8%; chemotherapy sessions grew 24%, indicating higher patient demand.
Emerging centers delivered 32% revenue growth with improving EBITDA margins, expected to boost overall margins.
Digital revenue doubled in FY '25; with efforts to scale digital channels further expected to contribute significantly to top-line growth.
New facilities: flagship 189-bed center in Ahmedabad operationalized; two new hospitals in Bangalore to come online in FY '26 to tap new markets and enhance capacity.
Plans to operationalize over 900 beds across the network within 3 years including 350 beds invested but not yet operational.

2 more points management made on revenue & sales performance

Profitability & Margins

HCG expects continued strong revenue and EBITDA growth in FY '26, building on a 16-18% revenue growth in FY '25 and a 44% EBITDA increase in emerging centers.
ARPOB (Average Revenue Per Occupied Bed) growth of 7-8% is anticipated for FY '26 due to shorter hospital stays and advanced treatments.
Expansion includes operationalizing 900+ beds over three years, including 350 already invested but not yet operational.
Emerging centers and new facilities like Ahmedabad and Bangalore are expected to drive higher ARPOB and margins, aiming for stable EBITDA margins in the low 20% range in the near future.
PAT is expected to normalize and improve as EBITDA scales, offsetting higher depreciation and interest costs from recent expansions and acquisitions.

2 more points management made on profitability & margins

See what Healthcare Global Enterprises Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

FY '26 Capex planned at approximately INR 286 crores focused on network expansion and technology upgrades, including existing centers in Bangalore and Cuttack.
Addition of over 900 beds across the network within the next 3 years, including 350 beds fully invested but not yet operational.
Investment in advanced technologies such as linear accelerator (LINAC) machines, PET-CT scanners, and robotic surgery platforms to enhance precision cancer care.
Two new hospitals to commence operations in Bangalore in FY '26: one in North Bangalore (second half of FY '26) and another in Whitefield as an extension of the flagship center.

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹649 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

Healthcare Global Enterprises Limited is considering a primary equity infusion with the incoming new investor KKR expected to replace CVC.
The primary equity infusion is aimed partly at reducing debt, thereby lowering interest costs and improving PAT.
No specific amount or timeline has been disclosed yet; the decision will be made in the coming few months.
Current year's capex is about INR 280 crores, mostly funded from internal accruals, with no concrete plans for further growth capex beyond this.

2 more points management made on fundraising & capital structure

See what Healthcare Global Enterprises Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not provide explicit details on the current or expected order book or pending orders for Healthcare Global Enterprises Limited. However, some relevant points related to capacity expansion and investments include: - Plans to operationalize over 900 beds across their network within the next 3 years, including 350 beds already fully invested but not yet operational (Page 6). - Growth capex guidance of approximately INR 280-286 crores in FY '26, aligned with network expansion and technology upgrades (Pages 6 and 10).

2 more points management made on order book & pipeline

Healthcare Global Enterprises Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹652 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Health.Global's management said in earlier quarters

Others in Healthcare Services this season

3B Blackbio DX Ltd (Q4 FY25)
UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Key concall takeaways from 3B Blackbio DX…
Apollo Hospitals Enterprise Ltd (Q4 FY25)
. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
Shalby (Q4 FY25)
Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…
Suraksha Diagno. (Q4 FY25)
Volume of tests conducted has been growing at around 10% year-on-year between FY '24 and FY '25. Key concall takeaways from Suraksha Diagnostic Ltd's Q4 FY25…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Healthcare Global Enterprises Ltd Q4 FY25 results?

What is Healthcare Global Enterprises Ltd share price analysis?

Healthcare Global Enterprises Ltd currently shows a neutral. The stock trades at a P/E of 221.3 with a market cap of ₹10,665 Cr. Investors should review the full earnings analysis for detailed insights.

Is Healthcare Global Enterprises Ltd planning capital expenditure?

FY '26 Capex planned at approximately INR 286 crores focused on network expansion and technology upgrades, including existing centers in Bangalore and Cuttack.

Keep Healthcare Global Enterprises Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.